Trodelvy Keytruda Combination Delivers Breakthrough Results in Metastatic Triple-Negative Breast Cancer

By João L. Carapinha

April 30, 2025

A Phase III trial (ASCENT-04/KEYNOTE-D19) has shown that the Trodelvy Keytruda combination improves progression-free survival over Keytruda plus chemotherapy in previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC). This pivotal study is the first to demonstrate superiority for a TROP-2 antibody-drug conjugate combined with an immuno-oncology agent in first-line mTNBC treatment.

Improving Treatment Options

The Trodelvy Keytruda combination marks a groundbreaking approach. It is the first time an antibody-drug conjugate (ADC) paired with immunotherapy has shown potential in early metastatic breast cancer treatment. As Dietmar Berger, Chief Medical Officer at Gilead Sciences, highlights, this therapy could redefine options for patients with this challenging cancer.

The ASCENT-04/KEYNOTE-D19 trial was a global, open-label, randomized study involving 443 patients with untreated, PD-L1-positive (CPS ≥ 10) metastatic TNBC. Participants received either:

  • 10 mg/kg of Trodelvy on days one and eight of a 21-day cycle plus 200 mg of Keytruda on day one, or
  • Chemotherapy (gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel) combined with Keytruda.

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate targeting Trop-2, a protein overexpressed in epithelial cancers. It uses a humanized monoclonal antibody linked to SN-38, the active metabolite of irinotecan, which disrupts topoisomerase I and induces cell death. Unlike conventional chemotherapy, this targeted approach may spare normal cells.

Contextualizing Triple-Negative Breast Cancer

TNBC makes up 10-15% of breast cancer cases. It is hard to treat because it does not respond to hormone or targeted therapies. Current standard treatments give patients only 5-7 months of progression-free survival before disease progression.

In 2020, the FDA approved pembrolizumab (Keytruda) plus chemotherapy for advanced TNBC patients with PD-L1 scores ≥10. This combo improved progression-free survival over chemotherapy alone. Trodelvy is already approved for advanced TNBC patients with at least two prior therapies and for certain metastatic breast cancer cases.

Health Economics and Patient Outcomes

The Trodelvy Keytruda combination improves progression-free survival significantly. This may enhance patients’ quality of life and reduce healthcare use linked to disease progression. If long-term data show better overall survival, its value could grow further.

Gilead will present detailed study results soon and engage with regulators. The safety profile aligns with each drug’s known risks, which may ease approval. However, Trodelvy’s boxed warnings for neutropenia and severe diarrhea could affect reimbursement and treatment protocols.

Future Research Directions

Gilead is studying Trodelvy in more trials, including for PD-L1-negative TNBC patients. This shows confidence in the drug’s broader potential and could reshape TNBC treatment. For more details, see the findings on the Trodelvy Keytruda combination here.

Reference url

Recent Posts

biosimilars price competition
            

Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Market Sustainability

💡 Are biosimilars the key to transforming U.S. healthcare costs?

A recent study reveals that as more biosimilars enter the market, original product prices drop significantly—by as much as 10-13% per competitor! This shift has led to astonishing savings, totaling $23.6 billion for Medicare between 2015 and 2023. However, concerns linger about the long-term sustainability of this competitive pricing environment.

Dive into the insights on how this booming market balances immediate cost reductions with potential future challenges.

#SyenzaNews #HealthEconomics #Pharmaceuticals #HealthcarePolicy

MFN drug pricing
       

MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alignment

💡 Are U.S. and global drug prices set for a revolution?

The new Most-Favored-Nation (MFN) drug pricing policy from the HHS and CMS aims to align U.S. pharmaceutical prices with those in economically comparable countries, promising significant reductions without stifling innovation. This bold move could lead to more accessible medications for Americans while reshaping global pricing strategies.

Curious about how this might impact your commercial and pricing strategy? Dive into the details!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation #DrugPricing

HTA reform analysis
         

HTA Reform Analysis: Patterns and Global Trends in Health Technology Assessment

🌍 Ever wondered how health technology assessment (HTA) reforms shape global healthcare?

Our latest article provides a comprehensive analysis of HTA reforms across 14 international agencies, highlighting the evolving roles of “catalysts,” “traditionalists,” and “observers.” Discover how international collaborations are pivotal in advancing HTA methodologies and ensuring patient involvement in assessment processes.

Jump into the intricacies of HTA reforms and optimize your health economics strategies!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.